Sunday, October 23, 2011
Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials In Patients With Type 1 And Type 2 Diabetes
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the insulin analog comparator, with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment